Alaunos Therapeutics, Inc. (TCRT)
NASDAQ: TCRT · Real-Time Price · USD
3.075
+0.072 (2.40%)
At close: Jun 13, 2025, 4:00 PM
3.148
+0.073 (2.38%)
After-hours: Jun 13, 2025, 4:19 PM EDT
Company Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders.
The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass.
It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression. In addition, the company develops hunTR TCR discovery platform to target driver mutations.
Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.
Alaunos Therapeutics, Inc.
| Country | United States |
| Founded | 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Dale Hogue |
Contact Details
Address: 2617 Bissonnet Street, Suite 233 Houston, Texas 77005 United States | |
| Phone | 346 355 4099 |
| Website | alaunos.com |
Stock Details
| Ticker Symbol | TCRT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001107421 |
| CUSIP Number | 98973P101 |
| ISIN Number | US98973P3091 |
| Employer ID | 84-1475642 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dale Curtis Hogue Jr. | Interim Chief Executive Officer and Director |
| Ferdinand Groenewald | Vice President of Finance |
| Melinda Lackey | Senior Vice President of Legal, Administration and Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 10, 2025 | 8-K | Current Report |
| May 23, 2025 | 8-K | Current Report |
| May 21, 2025 | ARS | Filing |
| May 21, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 21, 2025 | DEF 14A | Other definitive proxy statements |
| May 15, 2025 | 10-Q | Quarterly Report |
| May 14, 2025 | SCHEDULE 13D | Filing |
| May 9, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 30, 2025 | 10-K/A | [Amend] Annual report |
| Apr 18, 2025 | 8-K | Current Report |